Active, not recruitingPhase 2NCT05556746

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Brigham and Women's Hospital
Principal Investigator
Serena Koenig, MD, MPH
Brigham and Women's Hospital
Intervention
Bedaquiline(drug)
Enrollment
94 enrolled
Eligibility
18 years · All sexes
Timeline
20232027

Study locations (2)

Collaborators

University of Cape Town · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic · University of Stellenbosch · University of California, Los Angeles · Harvard School of Public Health (HSPH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05556746 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials